RECRUITING

Interprofessional Pharmacogenomics (IPGx) Registry and Repository

Talk to us

Conditions

DiabetesCholesterolCancerBlood Pressure DisordersHeart DiseaseRespiratory IlnessCOPDAdverse Drug Reaction (ADR)Poly PharmacyREGISTRYREPOSITORYPOLYPHARMACYADVERSE DRUG REACTION

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This program collects genetic and health information to help doctors choose the right medications for patients.

Official Title

The Texas Interprofessional Pharmacogenomics Registry and Repository

Quick Facts

Study Start:2025-01
Study Completion:2029-11
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06726590

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * The study will invite patients who are eligible for PGX workup/PGX care to participate, provided they meet the following criteria: Use of five or more medications, including over the counter drugs, supplements, natural products, cannabis products, or other recreational drugs, or
  2. * Individuals taking blood pressure or depression medications, even if less than five medications.
  3. * Ability to understand and give consent.
  4. * Able to consent to donate blood and/or urine samples and buccal swabs.
  5. * Able to answer detailed questionnaires, including quarterly questionnaires about ADRs, cognitive testing such as serial mini-mental status exams, and or quality of life questions.
  6. * Able to understand that their health record and changes in health status will be followed for a five-year period and shared in deidentified form with the research community.
  7. * All genders.
  8. * Any age over 18 years.
  1. * Individuals admitted to hospice.
  2. * Declines to participate or interact with staff/share their medical status.
  3. * A diagnosis of Alzheimer's disease or related dementias in a medical record as this indicates a progressive, debilitating condition that impairs memory, thought processes, and functioning.,
  4. * Individuals who are unable or unwilling to provide consent.
  5. * Unable to verbally communicate and comprehend English language

Contacts and Locations

Study Contact

Kenneth S Ramos, MD, PhD
CONTACT
(713) 677-7440
kramos@tamu.edu
Rick Silva, PhD
CONTACT
ricksilva@tamu.edu

Study Locations (Sites)

Texas A&M Family Care
Bryan, Texas, 77802
United States

Collaborators and Investigators

Sponsor: Texas A&M University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01
Study Completion Date2029-11

Study Record Updates

Study Start Date2025-01
Study Completion Date2029-11

Terms related to this study

Keywords Provided by Researchers

  • REGISTRY
  • REPOSITORY
  • POLYPHARMACY
  • ADVERSE DRUG REACTION

Additional Relevant MeSH Terms

  • Diabetes
  • Cholesterol
  • Cancer
  • Blood Pressure Disorders
  • Heart Disease
  • Respiratory Ilness
  • COPD
  • Adverse Drug Reaction (ADR)
  • Poly Pharmacy